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Abstract Ligand binding to the thyroid hormone nuclear
receptor L1 (TRL1) is inhibited by desethylamiodarone (DEA),
the major metabolite of the widely used anti-arrhythmic drug
amiodarone. Gene expression of thyroid hormone (triiodothyr-
onine, T3)-regulated genes can therefore be affected by
amiodarone due to less ligand binding to the receptor. Previous
studies have indicated the possibility of still other explanations
for the inhibitory effects of amiodarone on T3-dependent gene
expression, probably via interference with receptor/co-activator
and co-repressor complex. The binding site of DEA is postulated
to be on the outside surface of the receptor protein overlapping
the regions where co-activator and co-repressor bind. Here we
show the effect of a drug metabolite on the interaction of TRL1
with the co-activator GRIP-1 (glucocorticoid receptor inter-
acting protein-1). The T3-dependent binding of GRIP-1 to the
TRL1 is disrupted by DEA. A DEA dose experiment showed that
the drug metabolite acts like an antagonist under ‘normal’
conditions (at 1037 M T3 and 5U1036C1033 M DEA), but as
an agonist under extreme conditions (at 0 and 1039 M T3 and
s 1034 M DEA). To our knowledge, these results show for the
first time that a metabolite of a drug which was not devised for
this purpose can interfere with nuclear receptor/co-activator
interaction. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Hormones can in£uence transcription via binding to their
speci¢c nuclear receptors. Occupancy of binding sites with
ligand results in conformational changes of the receptor pro-
tein, allowing dissociation of co-repressors and association of
the hormone^receptor complex with nuclear co-activators.
This sequence of events ultimately leads to modulation of
the transcription rate of the hormone-responsive genes [1].
The role of nuclear co-repressors and co-activators in tran-
scriptional regulation has only recently become apparent.
Their biological relevance is highlighted by the ¢nding that
particular mutations in the human thyroid hormone receptor
L1 (hTRL1) disturb the interaction between co-activator and
co-repressor interactions and thyroid hormone receptor (TR),
resulting in thyroid hormone resistance [2]. Desethylamiodar-
one (DEA), the major metabolite of the powerful anti-ar-
rhythmic and anti-anginal drug amiodarone, is a non-compet-
itive inhibitor of the binding of triiodothyronine (T3) to the
thyroid hormone receptor L1 (TRL1) protein [3], its binding
site is postulated to be on the outside surface of the receptor
protein overlapping the regions where co-activator and co-re-
pressor bind [4]. Here we report that DEA can also a¡ect the
binding of co-activator glucocorticoid receptor interacting
protein-1 (GRIP-1) to the ligand^receptor complex.
Amiodarone is widely used in the treatment of a variety of
cardiac diseases. It is a peculiar drug in view of its extensive
tissue accumulation (notably in the liver, lung and adipose
tissue) and very long elimination half-life. Characteristic struc-
tural features are its resemblance to thyroxine and its high
iodine content. The release of pharmacological quantities of
iodine during biotransformation of the drug results in iodine-
induced thyrotoxicosis and hypothyroidism in a minority
(about 16%) of patients. In contrast, in almost every patient
treated with amiodarone, hypothyroid-like e¡ects are ob-
served in the expression of various T3-responsive genes. Ex-
amples are the decrease in L-adrenoreceptor density and
Na,K-ATPase activity in the heart, and the decrease of low
density lipid (LDL)) receptor density in the liver as evident
from studies in humans and in experimental animals [5^8].
These hypothyroid-like e¡ects can be reversed by the admin-
istration of T3, and are explained from a decreased transcrip-
tion of involved genes [9]. For example, the increase in serum
LDL cholesterol observed in amiodarone-treated patients [10]
is caused by a decreased expression of the hepatic LDL re-
ceptor protein, which is due to a decreased transcription of
the gene encoding the LDL receptor. The decrease in tran-
scription might well be caused by a lower T3 receptor occu-
pancy as amiodarone substantially decreases the generation of
T3 out of T4 in the liver by inhibition of type I deiodinase [11].
Furthermore, DEA has been shown to be a competitive in-
hibitor of the binding of T3 to thyroid hormone receptor K1
(TRK1) [12] and a non-competitive inhibitor with respect to
TRL1 [3]. Further insight into this antagonistic e¡ect of DEA
on T3 receptor binding was obtained by evaluating the
changes in the molecular constitution of either the drug or
the receptor. We have previously reported the results of com-
petition studies with amiodarone analogues: the bulky iodine
atoms, the hydrophobicity, the electric charge and the overall
size of the analogues markedly in£uenced the nature and po-
tency of their inhibition on T3 receptor binding [13]. These
studies, however, did not provide further information on the
localization of the DEA binding site on the receptor. There-
fore we studied the e¡ect of naturally occurring and arti¢cial
mutations in TRL1 which were known to decrease T3 a⁄nity.
The results of these studies demonstrated that amino acids
E457 and R429 are at or near the DEA binding site on the
receptor [4]. Since these residues may be involved in co-acti-
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vator (E457) [14] or co-repressor (R429) [15,16] interaction,
this ¢nding led us to hypothesize a possible disruption of the
TRL1^co-activator interaction by DEA. The aim of the
present study was to verify this hypothesis by studying the
in£uence of DEA on the T3-dependent binding of co-activator
GRIP-1 to hTRL1.
2. Materials and methods
2.1. Chemicals
T3 was obtained from Henning (Berlin, Germany). DEA from
Sano¢ Recherch (Montpellier, France) was used as a 1032 M stock
solution in ethanol.
2.2. Protein expression
Co-activator GRIP-1 was expressed as a glutathione-S-transferase
(GST)-GRIP-1-nuclear receptor interacting domain (NID) fusion pro-
tein containing the NID of the co-activator GRIP-1 attached to GST.
This fusion protein was expressed in Escherichia coli as described
previously [17].
TRL1 (amino acids 153^461) was cloned with a hemagglutinin epi-
tope-tag (HA-TRL1) at the N-terminus which did not interfere with
the hormone binding domain at the C-terminus. The HA-TRL1 was
expressed in E. coli and isolated as described before [17,18].
2.3. Pull-down assay
To study the receptor co-activator interaction in the presence of
DEA, we used a recently developed non-radioactive ‘pull-down’ assay
[18]. In short, GST-GRIP-1-NID bound to glutathione^Sepharose
beads was resuspended in binding bu¡er (20 mM HEPES, pH 7.9,
80 mM KCl, 10 mM MgCl2, 10% glycerol, 1 mM dithiothreitol
(DTT), 0.1% NP-40, 0.1% Triton X-100; Complete (EDTA free) pro-
tease inhibitor (Roche)). HA-TRL1-containing lysate (8 Wl) was di-
luted to 20 Wl with binding bu¡er containing 20 Wl/ml bovine serum
albumin and preincubated with or without T3 and in the absence or
presence of DEA for 30 min at 4‡C. Thereafter GST-GRIP-1-NID
beads were added and the incubation continued for 90 min at 4‡C
whilst shaking. The samples were washed, dried and resuspended in
protein loading bu¡er containing 5 mM DTT. They were run on a
10% sodium dodecyl sulfate (SDS)^polyacrylamide gel electrophoresis
gel blotted onto PVDF membrane (Roche) using a transfer bu¡er
without SDS and lowered methanol (15%).
For detection of the HA-tag, the blot was incubated with a high
a⁄nity monoclonal anti-HA antibody conjugated with peroxidase
(POD) (anti-HA 3F10-POD). Using Lumi-Lightplus substrate (Roche),
the chemiluminescent signal was detected and quanti¢ed using a Lumi
Imager (Roche). Average exposure time was 2 min.
To investigate whether DEA had an e¡ect on this protein^protein
interaction two sets of experiments were performed. First the dose
e¡ect of T3 was studied in the absence and presence of a constant
amount of DEA. TRL1 was preincubated with thyroid hormone (T3)
over a concentration range of 3U10310 up to 1037 M T3 in the
absence and presence of 1035 M DEA. In the second set of experi-
ments, the dose-dependent e¡ect of DEA was studied. TRL1 was
preincubated with DEA over a concentration range of 1036 up to
1033 M DEA in the absence of T3 and in the presence of 1039 M
and 1037 M T3.
3. Results
The results of the T3 dose e¡ect experiments indicate a T3
dose dependency of the binding of GRIP-1 to the TRL1,
which was observed previously [19]. The binding of GRIP-1
to the TRL1 increased at higher T3 and was lower in the
presence of 1035 M DEA at all T3 concentrations tested
(Fig. 1a) (P6 0.0001; ANOVA, two way with replication;
n = 3). Individual points of the binding curves di¡er signi¢-
cantly at 3U1038 M (P6 0.01; n = 5) and at 1037 M
(P6 0.05; n = 4) (Fig. 1b). The HA-TRL1 protein binds T3
with wild type a⁄nity (KD 0.3U1039 M).
A DEA dose-dependent e¡ect of the binding of GRIP-1 to
the TRL1 was also observed. In the absence of T3, the binding
of GRIP-1 to TRL1 remains very low at DEA concentrations
up to 1035 M (Fig. 2a); however, a 10-fold increase is ob-
served in the presence of 1033 M DEA. It appears therefore
that DEA acts as an agonist with respect to the unoccupied
TRL1. In the presence of 1039 M T3, the DEA-induced in-
crease in binding is less pronounced and signi¢cantly di¡erent
from that obtained in the absence of T3 (P6 0.001; ANOVA,
two-factor with replication; n = 4) (Fig. 2b). Interestingly, at
1037 M T3, a reversal of the dose^response pattern is seen and
the binding curve di¡ers signi¢cantly from the other two
(P6 0.001; ANOVA, two-factor with replication; n = 4). At
a T3 concentration of 1037 M, the highest binding of GRIP-1
to TRL1 is observed in the absence of DEA, and the binding
decreases in the presence of DEA in a dose-dependent manner
(Fig. 2a,b).
4. Discussion
From the above results, we conclude that DEA can act as a
Fig. 1. a: Western blots of HA-TRL1, depicting the dose-dependent
e¡ect of T3 on the binding of TRL1 to GRIP-1 in the absence and
presence of 1035 M DEA. Lane 1: 10% of HA-TRL1 input. Lanes
2^8: binding in the presence of 0; 3U10310 ; 6U10310 ; 1039 ;
3U1039 ; 3U1038 ; 1037 M T3, respectively, in the absence of DEA.
Lanes 9^15: binding in the presence of 0; 3U10310 ; 6U10310 ;
1039 ; 3U1039 ; 3U1038 ; 1037 M T3, respectively, in the presence
of 1035 M DEA. HA-TRL1 was detected by anti-HA-POD and
chemiluminescent substrate. b: Dose^response e¡ect of T3 on the
binding of TRL1 to GRIP-1 in the absence (b) and presence (R) of
1035 M DEA. Quanti¢cation and plot of the light units from West-
ern blot (a), measured by the Lumi Imager. The relative binding is
the ratio of the observed binding of TRL1 to GRIP-1 to the (maxi-
mal) binding at 1037 M T3 in the absence of DEA.
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partial antagonist: the actual mode of action depends on the
ambient T3 concentration. This phenomenon can be explained
from the non-competitive nature of the inhibition of T3 bind-
ing to TRL1 by DEA. This non-competitiveness allows the
formation of both the complexes DEA/TRL1 and DEA/T3/
TRL1, since the binding sites of T3 and DEA are not the
same. Only in the case of DEA/T3/TRL1 will there be antag-
onism, i.e. there must be some T3 present for DEA to act as
an antagonist.
In order to relate these in vitro ¢ndings to the in vivo
situation, T3 and DEA concentrations in our experiments
must be compared with tissue levels in vivo. In human serum,
T3 values are in the order of 1039 M and DEA levels in the
order of 2U1036 M [20] in patients on long-term amiodarone
treatment. Rat liver T3 and DEA levels are reported to be
about 1038 mol/kg [11] and 1.2U1035 mol/kg [21], respec-
tively. In human liver, DEA concentration can reach
4U1033 mol/kg [22]. A thousand times higher DEA concen-
tration in liver and other tissues compared to T3 is therefore
possible. The actual intracellular T3 and DEA levels are not
known, but taking into account the above mentioned serum
and tissue concentrations, our in vitro model may well repre-
sent the in vivo situation in the human cell. DEA is a very
lipophilic drug and accumulates substantially in tissues during
amiodarone treatment. The drug also inhibits T4 5P-deiodina-
tion into T3 resulting in a substantial decrease of intracellular
T3 levels and lower TR occupancy [11]. At a ‘normal’ receptor
occupancy of about 50%, the e¡ect of DEA will be limited.
However, at higher DEA concentrations and especially in the
case of a decreased T3 occupancy of the binding sites, DEA
will act as an antagonist, resulting in lower co-activator bind-
ing.
Simpli¢ed, T3-dependent gene regulation can be seen as an
on/o¡ switch (with or without ligand), whereas in the ¢ne
tuning of this process many other proteins are involved.
This complex regulation system thus forms a balance between
hormone, receptor, co-activators, co-repressors and other pro-
teins involved in the transcription machinery. DEA interferes
in this balance in three ways. First, by inhibiting deiodination
of T4 to T3 in the liver [11]. Second, by a non-competitive
inhibition of the binding of T3 to the TRL1 [3]. And third, by
disrupting the binding of co-activator GRIP-1 to the TRL1
(this study).
Overall we postulate that not amiodarone itself, but its
stable major metabolite DEA interferes with T3-dependent
gene expression [23] by interfering with the binding of T3 to
the thyroid hormone receptor and disrupting the co-activator/
TR binding. This mechanism of action would explain the T3
Fig. 2. a: Western blots of HA-TRL1, depicting the dose-dependent e¡ect of DEA on the binding of TRL1 to GRIP-1 in the presence of 0,
1039 or 1037 M T3. Lanes 1^6: binding in the absence of T3 and in the presence of 0; 1036 ; 5U1036 ; 1035 ; 1034 ; 1033 M DEA, respectively.
Lanes 7^13: binding in the presence of 1039 M T3 and in the presence of 0; 1036 ; 5U1036 ; 1035 ; 5U1035 ; 1034 ; 1033 M DEA, respectively.
Lanes 7^13: binding in the presence of 1037 M T3 and in the presence of 0; 1036 ; 5U1036 ; 1035 ; 5U1035 ; 1034 ; 1033 M DEA, respectively.
Lane 21: 10% of HA-TRL1 input. b: Dose^response e¡ect of DEA on the binding of TRL1 to GRIP-1 in the absence of T3 (R) and in the
presence of 1039 M T3 (E) and 1037 M T3 (b). Quanti¢cation and plot of the light units from Western blot (a), measured by Lumi Imager.
The light units are expressed as BLUs (Boehringer Light Units). The crossing of the lines at high and low T3 concentration is indicative for
partial antagonism.
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antagonistic e¡ects of DEA observed in patients on long-term
amiodarone treatment.
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